NEUROCRINE BIOSCIENCES INC 8-K

What Happened Neurocrine Biosciences, Inc. (NBIX) filed an 8-K on May 28, 2026 reporting that its stockholders approved an amendment to the company’s 2025 Equity Incentive Plan (the “Amended 2025 Plan”) at the 2026 Annual Meeting of Stockholders. The company’s definitive proxy statement that describes the material terms of the Amended 2025 Plan was filed with the SEC on April 15, 2026 and is incorporated by reference in the 8-K.

The filing also lists Item 5.02 (Departure of Directors or Certain Officers; Election of Directors), but the excerpt provided does not include substantive details of any specific officer or director change referenced by that item.

Key Details

• Vote action: Stockholders approved an amendment to the 2025 Equity Incentive Plan at the 2026 Annual Meeting.
• Reference doc: Material terms are summarized in the definitive proxy statement filed April 15, 2026.
• 8-K filing date: May 28, 2026.
• Item 5.02 is noted in the filing, but no further details were included in the provided excerpt.

Why It Matters Approval of an amended equity incentive plan is important for investors because it governs the company’s ability to grant stock-based awards (options, restricted stock, RSUs) to employees and executives. Such plans can affect executive incentives and future dilution of shares outstanding. Retail investors should review the April 15, 2026 proxy (or the full 8-K) for specifics on share reserves, award types, and potential dilution to understand the concrete impact on shareholder value.